Certain Features of Polycythemia Vera Increase Symptom Burden

Share this content:
Patients with polycythemia vera who have known hydroxyurea use, known phlebotomy, or splenomegaly have significant symptoms.
Patients with polycythemia vera who have known hydroxyurea use, known phlebotomy, or splenomegaly have significant symptoms.

Patients with polycythemia vera who have known hydroxyurea use, known phlebotomy, or splenomegaly have significant polycythemia vera-associated symptoms, a new study published online ahead of print in the Journal of Clinical Oncology has shown.1

Recent evidence has demonstrated the efficacy of JAK inhibitor therapy, like ruxolitinib, in patients with polycythemia vera who have a history of the aforementioned features.

Because polycythemia vera, a myeloproliferative neoplasm, is associated with disabling symptoms and an increased risk of life-threatening complications, researchers sought to determine how prior hydroxyurea use, phlebotomy requirements, and palpable splenomegaly contribute alone and in combination to the symptom burden of the disease.

For the study, researchers prospectively evaluated 1334 patients with polycythemia vera who had characterized symptom burden. Results showed that the presence of each feature was associated with a moderately high symptom burden. Researchers found that the association persisted despite the patient's polycythemia vera risk category.

RELATED: Ruxolitinib Superior to Standard Therapy for Polycythemia Vera

The study also demonstrated that symptoms incrementally increased in severity with additional features. Patients who had all 3 features had the highest symptom burden but had similar individual symptom burden compared with patients with known hydroxyurea use, known phlebotomy, and splenomegaly.

The findings demonstrated “that many [polycythemia vera] symptoms remain severe independent of the number of features present,” the authors concluded.

Reference

  1. Geyer H, Scherber R, Kosiorek H, et al. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease [published online ahead of print November 23, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.62.9337.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters